



EMLc

Codes ATC: V03AF01

|                                     |   |
|-------------------------------------|---|
| <b>Indication</b>                   | Osteosarcoma of bone and articular cartilage of other specified sites<br>Code ICD11: 2C21.Y   |
| <b>INN</b>                          | Mesna   |
| <b>Type de médicament</b>           | Chemical agent  |
| <b>Type de liste</b>                | Liste complémentaire (EML)<br>(EMLc)  |
| <b>Formulations</b>                 | Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule<br>Oral > Solid: 400 mg ; 600 mg |
| <b>Historique des statuts LME</b>   | Ajouté pour la première fois en 2015 (TRS 994)  |
| <b>Sexe</b>                         | Tous  |
| <b>Âge</b>                          | Aussi recommandé pour les enfants   |
| <b>Équivalence thérapeutique</b>    | La recommandation concerne ce médicament spécifique   |
| <b>Renseignements sur le brevet</b> | Patents have expired in most jurisdictions<br>Lire la suite sur les brevets. ↗  |
| <b>Balises</b>                      | Cancer  |
| <b>Wikipédia</b>                    | Mesna ↗   |
| <b>DrugBank</b>                     | Mesna (Coenzyme M) ↗  |

## Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for mesna on the complementary list of the EML and EMLc for use in treatment protocols for osteosarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for osteosarcoma is attached.

Rapport du comité d'experts ↗

